The Role of Targeted Therapy in the Management of Pancreatic Cancer

1
The Role of Targeted Therapy in the Management of
Pancreatic Cancer
2
How Can We Use Small Molecules with Chemotherapy?
3
(No Transcript)
4
Synergistic Effect of GTX and RAF-1 Inhibitor on
MEK1/2 Kinase
5
Synergistic Effect of GTX and RAF-1 Inhibitor on
Apoptosis of PC Cells
6
Agenda
7
Rationale for Targeted Therapy in PC
8
(No Transcript)
9
S0205 Overall Survival
10
S0205 Tumor Response
11
S0205 Conclusions
12
ECOG 8200 Rand. Phase IIIrinotecan Docetaxel
/- Cetuximab
13
Significance of ECOG 8200
14
VEGF as a Target in Pancreatic Cancer
15
(No Transcript)
16
(No Transcript)
17
Response Data
18
(No Transcript)
19
Gemcitabine Biologic Combinations
20
Future Directions
21
(No Transcript)
22
New Targets in Pancreatic Cancer from the
Laboratory
23
Proposed Mechanism of Action of AAA
24
(No Transcript)
25
p16/KRas Transgenic Micep16 Knock-out / Mutant
K-Ras Knock-in (G12D)
26
(No Transcript)
27
New Targets in Pancreatic Cancer from the
Laboratory
28
(No Transcript)
29
(No Transcript)
30
(No Transcript)
31
Curcumin (2.5 mM) and Erlotinib (5 mM) Treated
PANC1 Cells for 48 hours and then Mitomycin
(100 ng/ml) for Another 48 hours with Annexin V
Assay
32
Summary
33
Summary